Androgenetic alopecia Androgenetic alopecia, hair preparations, randomized controlled trials, treatment outcomes, photography, self-report, minoxidil
Conditions
Interventions
Topical formulation containing 5% Procapil was administered four puffs twice daily to affected scalp regions. Monthly follow ups evaluated treatment outcomes through a self-assessment questionnaire, g
Active Comparator Drug,Active Comparator Drug
5% Procapil,5% Minoxidil
Sponsors
COMBINED MILITARY HOSPITAL QUETTA
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. The male participants who had stage II-V AGA according to the Norwood-Hamilton criteria and female participants with AGA according to the Ludwig scale were included. 2. All participants ranged in age from 18 to 55 years. 3. The inclusion criteria required participants to have abstained from any topical or systemic treatment for androgenetic alopecia during the three months preceding enrollment 4. Participants who have provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Alternative etiologies of hair loss, such as (e.g., fungal infection such as tinea capitis, inflammatory or scarring alopecia), hyper-androgenism or other hormonal disorders 2. Hypersensitivity to the study drugs 3. Pregnancy or breastfeeding 4. Other severe systemic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair density baseline and 24 weeks after treatment Researcher evaluation of increased hair thickness ,Hair Quality baseline and 24 weeks after treatment Global photography scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient Satisfaction baseline and 24 weeks after treatment Questionnaire of patient's assessment of new hair growth and shrinkage in bald area | — |
Countries
Pakistan
Contacts
Public ContactNosheen Abbas
Combined Military Hospital Quetta
Outcome results
None listed